Results 41 to 50 of about 2,243,298 (271)

A rapid and systematic review of the clinical effectiveness and cost effectiveness of gemcitabine for the treatment of pancreatic cancer [PDF]

, 2001
Background Pancreatic cancer is the eighth most common cancer in the UK and the sixth most common cause of cancer death; in 1998, 3198 men and 3364 women died from this condition. In an average health authority with a population of 500,000, there
Calvert, N, Larvin, M., E. Morris, Bansback, N., Bansback, N, D. Radstone, Morris, E., D. Forman (12595714), A. Crellin (12595711), S. Ward (7130246), Forman, D., E. Morris (7786319), N. Calvert, Calvert, N., D. Radstone (12595720), Crellin, A., Larvin, M, Morris, E, D. Forman, Ward, S., A. Crellin, Radstone, D, S. Ward, N. Calvert (12595708), M. Larvin, N. Bansback (12595705), Forman, D, Ward, S, N. Bansback, Michael Larvin (12595717), Crellin, A   +30 more
core   +1 more source

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer [PDF]

, 2006
Background Anti-angiogenic treatment is believed to have at least cystostatic effects in highly vascularized tumours like pancreatic cancer. In this study, the treatment effects of the angiogenesis inhibitor Cilengitide and gemcitabine were compared with
Castellano Daniel, Kleeff Jörg, Vermorken Jan, Albert Abad Esteve, Simon van Belle, CASTELLANO, D, STOGER, H, Esteve, Albert Abad, Jochen Raedle, HERZOG, P, DAVIDSON, N, OETTLE, H, Balcke, Peter, SCHEITHAUER, W, DOBROWOLSKI, F, TEMPIA-CALIERA, AA, Neville Davidson, Langrehr, Jan M., Herzog Peter, Scheithauer Werner, Friess Helmut, HOSSFELD, DK, KOVAR, A, Herbert Stöger, Adrien A Tempia-Caliera, Jan M Langrehr, Neyns Bart, Bart Neyns, Castellano, Daniel, Oettle Helmut, Herzog, Peter, BALCKE, P, Dittrich, Christian, KATZ, F, Katz Frieder, Robert Hawkins, Hawkins Robert, Raedle, Jochen, PIEDBOIS, P, LANGREHR, JM, Pascal Piedbois, Werner Scheithauer, Dobrowolski, Frank, NIEDERGETHMANN, M, Nippgen Johannes, Hawkins, Robert, Van Belle, Simon, Piedbois Pascal, Raedle Jochen, Andreas Kovar, RAEDLE, J, HAWKINS, R, Stöger Herbert, Peter Balcke, Davidson, Neville, Tempia-Caliera, Adrien A., DITTRICH, C, Christian Dittrich, Hossfeld Dieter K, Tempia-Caliera Adrien A, Helmut Oettle, NIPPGEN, J, Esteve Albert, ESTEVE, AA, Balcke Peter, Friess, Helmut, Katz, Frieder, Oettle, Helmut, Hossfeld, Dieter K., Dobrowolski Frank, Peter Herzog, Daniel Castellano, Kleeff, Jörg, Niedergethmann Marco, Marco Niedergethmann, Dieter K Hossfeld, Jan Vermorken, Scheithauer, Werner, KLEEFF, J, Helmut Friess, Nippgen, Johannes, NEYNS, B, Jörg Kleeff, Dittrich Christian, Langrehr Jan M, Davidson Neville, Stöger, Herbert, Frank Dobrowolski, Frieder Katz, Kovar, Andreas, Johannes Nippgen, van Belle Simon, Niedergethmann, Marco, Vermorken, Jan, Kovar Andreas, FRIESS, H, Piedbois, Pascal, Neyns, Bart, VERMORKEN, J, Stoeger, Herbert, [et al.]   +100 more
core   +2 more sources

Understanding cisplatin resistance using cellular models [PDF]

, 2007
Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of the DNA adducts.
Davey, M, Davey, Mary W., Davey, Mary W, Stordal, B, Britta Stordal, Mary Davey, Stordal, Britta, Stordal, B., Davey, M.   +8 more
core   +2 more sources

Targeting the Microenvironment to Overcome Gemcitabine Resistance in Pancreatic Cancer [PDF]

Cancer Research, 2020
Abstract Pancreatic cancer is characterized by an extensive and complex microenvironment, and is resistant to both chemotherapy and immune checkpoint blockade. The study by Principe and colleagues in this issue of Cancer Research proposes a combinatorial approach based on targeting the very mechanisms of resistance to gemcitabine, a ...
Eileen S. Carpenter, Nina G. Steele, Marina Pasca di Magliano   +2 more
openaire   +2 more sources

Gemcitabine-induced Gli-dependent activation of hedgehog pathway resists to the treatment of urothelial carcinoma cells.

PLoS ONE, 2021
Patients with urothelial carcinoma (UC) experience gemcitabine resistance is a critical issue. The role of hedgehog pathway in the problem was explored.
Yu-Hao Chang, Hoi-Lam Tam, Meng-Chien Lu, Huei-Sheng Huang   +3 more
doaj   +1 more source

Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? [PDF]

, 2003
Background: Serial kinetics of serum CA 19-9 levels have been reported to reflect response and survival in patients with pancreatic cancer undergoing surgery, radiotherapy, and chemotherapy.
Stoffregen, C., Stemmler, J., Wilkowski, R., Garbrecht, M., Schalhorn, A., Lamerz, Rolf, Stieber, P., Szymala, A. M., Schermuly, M. M., Heinemann, Volker, Helmberger, T., Niebler, K.   +11 more
core   +1 more source

Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer [PDF]

, 2007
Objective: To date, no standard regimen for salvage chemotherapy after gemcitabine (Gem) failure has been defined for patients with advanced pancreatic cancer (PC). Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in
Haas, Michael, Haas, M., Wilkowski, R., Schulz, Christoph, Moosmann, Nicolas, Heinemann, V., Golf, Alexander, Bruns, Christiane J., Laessig, Dorit, Golf, A., Heinemann, Volker, Boeck, S., Moosmann, N., Issels, Rolf-Dieter, Wilkowski, Ralf, Laessig, D., Issels, R.D., Boeck, Stefan, Bruns, C.J., Schulz, C.   +19 more
core   +1 more source

Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis [PDF]

, 2012
Purpose The prognosis of patients with advanced and recurrent urothelial cancer (UC) is poor. Although cisplatin (CDDP)-containing chemotherapy is the most effective regimen in these patients, there is no other established chemotherapeutic regimen.
Tomohiro Matsuo, Ohba, Kojiro, Yuji Sagara, Nomata, Koichiro, Miyata, Yasuyoshi, Sakai, Hideki, Yasuyoshi Miyata, Kanetake, Hiroshi, Koichiro Nomata, Hiroshi Kanetake, Matsuo, Tomohiro, Sagara, Yuji, Kojiro Ohba, Hideki Sakai   +13 more
core   +1 more source

Gemcitabine and anthracyclines in platinum-resistant ovarian cancer

Annals of Oncology, 2006
Most of the patients with advanced ovarian cancer will recur after first-line platinum-based chemotherapy and need additional treatment. Gemcitabine (G) and Anthracyclines are active in this setting and their combination has shown synergistic antiproliferative activity in vitro, due to different mechanisms of action and non-overlapping toxicities.In ...
Galligioni, E., Arcuri, C., Sorio, R., Griso, C.   +3 more
openaire   +2 more sources

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group [PDF]

, 2005
Purpose: This phase III randomized trial compared two chemotherapy regimens, gemcitabine plus carboplatin and mitomycin, ifosfamide, and cisplatin, in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC).
Harper, P.G., Johnson, P.W.M., Harper, P. G., Qian, W., Rudd, R. M., Spiro, S.G., Gregory, W. M., Hatton, M., Eisen, T. G., James, L.E., Rankin, E. M., Johnson, P. W. M., Rankin, E.M., Spiro, S. G., Rudd, R.M., Lee, S. M., Littler, J. A. H., Lee, S.M., Littler, J.A.H., Eisen, T.G., Martin, W.M.C., Gregory, W.M., James, L. E., Gower, N. H., Martin, W. M. C., Gower, N.H.   +25 more
core   +1 more source